Serum cancer antigen 15.3 concentrations in patients with beta-thalassemia minor compared to those with cancer and healthy in-dividuals

Authors

  • Asghar Bazrafshan Hematology Research center, Shiraz University of Medical Sciences, Shiraz, Iran.
  • Javad Dehbozorgian Hematology Research center, Shiraz University of Medical Sciences, Shiraz, Iran.
  • Javad Dehghani Hematology Research center, Shiraz University of Medical Sciences, Shiraz, Iran.
  • Mahdi Shahriari Pediatric Hematology – Oncology Department, Nemazee Hospital, Shiraz University of Medical Sciences, Shiraz, Iran.
  • Mehran Karimi Hematology Research center, Shiraz University of Medical Sciences, Shiraz, Iran.
  • Peyman Eatemadfar Hematology Research center, Shiraz University of Medical Sciences, Shiraz, Iran.
  • Sezaneh Haghpanah Hematology Research center, Shiraz University of Medical Sciences, Shiraz, Iran.
Abstract:

  Background :Highserum level of cancer antigen 15.3 (CA15.3) has been reported in some malignant and nonmalignant conditions including thalassemia major which could have been resulted from ineffective erythropoiesis. We aimed to evaluate the serum level of CA15.3 in carriers of beta-thalassemia by comparing them with cancer patients and healthy individuals.   Methods : This cross-sectional study was done from February to December 2011 in Southern Iran. Participants consisted of 32 subjects with beta-thalassemia minor, 49 with cancer and 25 healthy individuals. The serum levels of CA15.3 were measured and compared in different groups.   Results : The serum levels of CA 15.3 in all participants were in the normal range (<35 U/mL). Also it did not significantly differ among various groups of the participants (p=0.723). Age was not significantly correlated with the serum level of CA 15.3 (r= 0.039, p=0.702). The most frequent cancer in the group of patients with malignancies was hematologic malignancies (96%) with the highest frequency for acute lymphoblastic leukemia (37 patients). Frequency of thalassemia minor in patients with cancer was 11 (22.4%).   Conclusion: Nocorrelation was found between CA 15.3 serum level with beta-thalssemia minor or with childhood malignancies. Compared to general population, a high proportion of beta-thalssemia minor was observed in patients with cancer in our study. Future prospective studies are needed to evaluate the relationship between cancer and beta-thalassemia minor accurately.

Upgrade to premium to download articles

Sign up to access the full text

Already have an account?login

similar resources

serum cancer antigen 15.3 concentrations in patients with beta-thalassemia minor compared to those with cancer and healthy in-dividuals

background :highserum level of cancer antigen 15.3 (ca15.3) has been reported in some malignant and nonmalignant conditions including thalassemia major which could have been resulted from ineffective erythropoiesis. we aimed to evaluate the serum level of ca15.3 in carriers of beta-thalassemia by comparing them with cancer patients and healthy individuals.   methods : this cross-sectional study...

full text

Serum cancer antigen 15.3 concentrations in patients with betathalassemia minor compared to those with cancer and healthy individuals

BACKGROUND High serum level of cancer antigen 15.3 (CA15.3) has been reported in some malignant and nonmalignant conditions including thalassemia major which could have been resulted from ineffective erythropoiesis. We aimed to evaluate the serum level of CA15.3 in carriers of beta-thalassemia by comparing them with cancer patients and healthy individuals. METHODS This cross-sectional study w...

full text

Evaluation of serum FGF23 in patients with beta-thalassemia major compared to healthy population and its associated factors

Background: The role of phosphate hemostasis in development of thalassemia bone disease has not been extensively studied yet. Due to the lack of sufficient human studies about the changes of serum Fibroblast growth factor-23(FGF23) in patients with beta-thalassemia major as the first step of investigating the role of FGF23 in thalassemia bone disease, the present study aimed to investigate the ...

full text

The Serum C-reactive Protein and Prooxidant-antioxidant Balance in Patients with Esophageal Cancer Compared to Healthy Subjects

Introduction: The molecular mechanisms involved in pathogenesis of esophageal cancer have been the main concern of several studies. In this study, we aimed to investigate the changes of serum prooxidant-antioxidant balance (PAB) value as a redox index, as well as serum C-reactive protein (CRP) compared to healthy control group. Materials and Methods: In a cross-sectional study, blood samples we...

full text

A Study of Leptin Serum Concentrations in Patients with Major Beta-Thalassemia

Background The aim of this study was to evaluate leptin serum levels in patients with major beta thalassemia which was also associated with their ferritin serum levels. Materials and Methods This case-control study was performed on 90 children -6 months to 16 years old, in Zabol, Amir- al- Momenin Hospital. Patients were divided in two groups and were matched in age and sex. All Children w...

full text

My Resources

Save resource for easier access later

Save to my library Already added to my library

{@ msg_add @}


Journal title

volume 28  issue 1

pages  588- 591

publication date 2014-01

By following a journal you will be notified via email when a new issue of this journal is published.

Keywords

Hosted on Doprax cloud platform doprax.com

copyright © 2015-2023